Determination of the recommended phase 2 dose: choice of design in an oncology trial
We are excited to share that at the 10th Statistics & Biopharmacy conference, our team is presenting an abstract on dose selection in oncology clinical trials. Co-authored by Lionel Riou França (Statistical Expert), Isabelle Josse, and Dorian Bankovic (Biostatistician), the study—“Determination of the recommended phase 2 dose: choice of design in an oncology trial”—was selected for the poster presentation session.
Explore the poster
The study, “Determining the Recommended Dose for Phase 2: Choosing the Design in a Clinical Trial in Oncology”, explores different approaches to determining the optimal dose for phase 2 trials. Selecting the right design is critical for balancing patient safety, treatment efficacy, and trial efficiency. Our findings indicate that the BOIN (Bayesian Optimal Interval) design outperformed other strategies in the setting we evaluated, providing clear guidance for clinical trial teams in oncology.
Check out our poster to dive deeper into the study, understand the methodology, and see the results firsthand.
Meet us at SnB 2025
Visit booth #6 to chat with Lionel Riou França and the Aixial team, discuss the research, and ask your questions. Don’t miss this opportunity to connect and explore innovative strategies in oncology trials.
TO GO FURTHER
How can we support your next project?
Whether you’re looking for a protocol review or a proposal,
simply reach out to us by filling our request for proposal.